{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T16:31:20.160587+00:00","company":{"ticker":"TMCI","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"fb43ec664b49f588b2d690618c79b8026b93ccb0","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2026-05-08T23:59:59+00:00","payload":{"eps_text":"$(0.28) per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(18.0) million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-08","result_type":"reported_results","revenue_text":"$47.2 million"},"claim":"TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2026 results: revenue $47.2 million, net income $(18.0) million, EPS $(0.28) per share. Guidance reaffirmed.","evidence_excerpt":"treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. • Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-213267","anchor_url":"https://secwatch.observer/filing/0001193125-26-213267#claim-fb43ec664b49f588b2d690618c79b8026b93ccb0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/0001193125-26-213267-index.htm"},{"fact_type":"earnings_release","fact_key":"da9fdff523c497d5fb3630ce3a903153666b9e7f","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2026-04-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":null,"report_date":null,"result_type":"preliminary_results","revenue_text":null},"claim":null,"evidence_excerpt":"The information contained in Item 7.01 of this Current Report on Form 8-K under the heading \"Preliminary, Unaudited First Quarter Outlook\" is incorporated by reference into this Item 2.02.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001630627-26-000010","anchor_url":"https://secwatch.observer/filing/0001630627-26-000010#claim-da9fdff523c497d5fb3630ce3a903153666b9e7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/0001630627-26-000010-index.htm"},{"fact_type":"debt_financing","fact_key":"836204fc936f4d562d75d4a03e75f9f3bdd678a4","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-12-18T23:59:59+00:00","payload":{"counterparty":"Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL","effective_date":"2025-12-16","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"3-Month SOFR plus 4.00%","item_codes_triggered":["2.03"],"maturity_text":"60 month","principal_text":"$30 million"},"claim":"TREACE MEDICAL CONCEPTS, INC. incurred revolving credit of $30 million with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at 3-Month SOFR plus 4.00% maturing 60 month.","evidence_excerpt":"The Revolving Loan Agreement establishes a 60 month revolving loan facility providing $30 million in additional borrowing capacity to the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-323802","anchor_url":"https://secwatch.observer/filing/0001193125-25-323802#claim-836204fc936f4d562d75d4a03e75f9f3bdd678a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000119312525323802/0001193125-25-323802-index.htm"},{"fact_type":"debt_financing","fact_key":"fa84951b1170daef627d2d1f51f50782be2d8eba","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-12-18T23:59:59+00:00","payload":{"counterparty":"SLR Investment Corp.","effective_date":"2025-12-16","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"1-Month SOFR plus 5.05%","item_codes_triggered":["2.03"],"maturity_text":"60 month","principal_text":"up to $125 million"},"claim":"TREACE MEDICAL CONCEPTS, INC. incurred term loan of up to $125 million with SLR Investment Corp. at 1-Month SOFR plus 5.05% maturing 60 month.","evidence_excerpt":"The Term Loan Agreement provides a 60 month term loan facility for up to $125 million in borrowing capacity to the Company over four tranches. At the loan closing, the Company drew $60 million under tranche one.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-323802","anchor_url":"https://secwatch.observer/filing/0001193125-25-323802#claim-fa84951b1170daef627d2d1f51f50782be2d8eba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000119312525323802/0001193125-25-323802-index.htm"},{"fact_type":"executive_change","fact_key":"33f08d1d48","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-04-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"John T. Treace was appointed as Chairman of the Board at TREACE MEDICAL CONCEPTS, INC..","evidence_excerpt":"appoint John T. Treace to serve as Chairman of the Board, effective upon the expiration of James T. Treace’s current term at the Company’s 2025 Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-051362","anchor_url":"https://secwatch.observer/filing/0000950170-25-051362#claim-33f08d1d48","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025051362/0000950170-25-051362-index.htm"},{"fact_type":"executive_change","fact_key":"89648a5d5c","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-04-07T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James T. Treace retired as Director at TREACE MEDICAL CONCEPTS, INC..","evidence_excerpt":"his intent to retire from the Board at the expiration of his current term at the 2025 annual meeting of stockholders","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-051362","anchor_url":"https://secwatch.observer/filing/0000950170-25-051362#claim-89648a5d5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025051362/0000950170-25-051362-index.htm"},{"fact_type":"earnings_release","fact_key":"d91be5a73b173841ec9182b7a7281d507dbd78e0","cik":1630627,"ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"($0.30) per share","guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":"($18.7) million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$51.1 million"},"claim":"TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2024 results: revenue $51.1 million, net income ($18.7) million, EPS ($0.30) per share. Guidance lowered.","evidence_excerpt":"through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023 • Gross margin of 80.2% in first quarter 2024 • First quarter 2024 net loss attributable to common stockholders was","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-054475","anchor_url":"https://secwatch.observer/filing/0000950170-24-054475#claim-d91be5a73b173841ec9182b7a7281d507dbd78e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm"}]}